Archive for June, 2011

Layne Christensen Co. (LAYN) surges on Q1 results

Wednesday, June 8th, 2011

Layne Christensen Co. (Nasdaq: LAYN) shares rose 13.8% to $31.19, after the provider of drilling and construction services reported first-quarter results that beat estimates. Volume of more than 127,000 has already outdistanced its daily average of 104,264.

The company, based in Mission Woods, Kansas, today announced net income for the first quarter ended April 30, 2011, of $13,066,000, or $0.66 per diluted share, compared to net income of $6,571,000, or $0.34 per diluted share last year.

Revenues for the three months ended April 30, 2011, increased $36,656,000, or 15.9%, to $267,371,000 compared to $230,715,000 for the same period last year.

Company CEO Andrew Schmitt led off the June 8, 2011 press release announcing the improved bottom line by commenting, “Layne Christensen Company had an all-time record first quarter in revenues and the third best first quarter in earnings, excluding the gain on sale of our Fontana, California facility.

“The Mineral Exploration Division was up significantly over last year in both revenues and earnings and the Water Infrastructure Division improved in an environment of continued weakness in municipal spending. Our Energy Division remains profitable despite very weak natural gas pricing. The markets in which we operate outside the U.S. still look very strong.”

For well over a century, Layne Christensen has been drilling deep to bring vital natural resources to the surface. Today, it claims to use the 21st century’s most advanced technologies to locate and produce water, minerals and energy – all essential to people’s lives every day.

Skyworks Solutions Inc. (SWKS) has above-average trading day on above-market growth

Tuesday, June 7th, 2011

Skyworks Solutions Inc. (Nasdaq: SWKS) shares rose 8.3% to $25.20 Tuesday, after the wireless semiconductor company affirmed its upbeat third-quarter forecast. Volume for the stock 10.8 million shares, more than double its daily average.

The Woburn, Mass.-based company is affirming its outlook for above-market growth, excluding its recently announced acquisitions. In April 2011, Skyworks guided to approximately $345 million in revenue with non-GAAP diluted earnings per share of $0.46 for the current quarter.

Further, during the earnings conference call, the Company indicated it was on a path to approach a $1.5-billion-revenue run rate with $2.00 in annualized non-GAAP diluted earnings per share in the September quarter. This growth outlook is being driven by the Company’s broad customer base, diversification into new markets and increasing share gains.

In the June 7 press release announcing the projections, Skyworks Chief Financial Officer, Donald Palette declared, “Skyworks’ core business continues to outperform our addressed markets and we believe this will be clearly reflected in our performance and guidance.

“To be clear,” Palette concluded, “our revenue and non-GAAP earnings outlook for both the June and September quarters is before we add the accretive SiGe and Advanced Analogic Technologies acquisitions.”

Skyworks Solutions, Inc. is an innovator of high reliability analog and mixed signal semiconductors. Leveraging core technologies, Skyworks offers diverse standard and custom linear products supporting automotive, broadband, cellular infrastructure, energy management, industrial, medical, military and mobile handset applications.

Temple-Inland Inc. (TIN) gallops on rejection of takeover bid

Tuesday, June 7th, 2011

Temple-Inland Inc. (NYSE: TIN) shares climbed 41.6% to $29.75 Tuesday, a day after International Paper Co. (NYSE: IP) made a $3.31-billion hostile bid for the maker of corrugated packaging and building products. Volume for Temple-Inland surpassed 10.8 million shares, trouncing an all-day average of 1.2 million.

The bid amounts to $30.60 per share. Monday, Temple-Inland’s Board of Directors, after careful consideration with its independent financial and legal advisors, voted unanimously to reject International Paper’s proposal after the Board determined unanimously that the proposal grossly undervalues Temple-Inland and is not in the best interest of Temple-Inland’s stockholders.

The Board authorized Temple-Inland CEO Doyle R. Simons, to communicate its rejection to John Faraci, International Paper’s Chairman and CEO. Simons stated, “Since we launched the ‘new’ Temple-Inland in January 2008, we have delivered superior results to our stockholders compared with our corrugated packaging peers (including IP), building products peers, and the S&P 500. Since that time, our total return to stockholders of 22% greatly exceeds the 5% total return that IP has achieved.

“Through our proven ability to execute our strategy focused on maximizing return on investment (ROI) and profitably growing our business, the Board believes the Company will continue to provide superior results for our stockholders,” continued Mr. Simons. “As the economic recovery continues and the benefits from our strategy continue to be realized, it is the stockholders of Temple-Inland who should gain from those anticipated benefits, not the stockholders of IP.”

The Austin-based Temple-Inland Inc. is a manufacturing company focused on corrugated packaging and building products. The fully integrated corrugated packaging operation consists of seven mills and 59 converting facilities.

ADA-ES Inc. (ADES) stock hikes after sale of joint-venture interest

Monday, June 6th, 2011

ADA-ES Inc. (Nasdaq: ADES) stock surged 54.7% to $15.47 Monday afternoon, on word it was selling its Clean Coal Solutions LLC holdings to an affiliate of Goldman Sachs. Volume of 594,000 shares proved nearly six times its normal daily average.

The sale concerns a 15.8% equity interest in Clean Coal, ADA’s 50:50 joint venture with an affiliate of NexGen Resources Corporation, by ADA and NexGen for $60 million to GSFS Investments I Corp., an affiliate of The Goldman Sachs Group, Inc. Closing of the transaction was simultaneous with signing.

Clean Coal’s patented coal technology, CyClean, is a cost-effective coal technology to produce Refined Coal, which reduces emissions of NOx and mercury.

Dr. Michael D. Durham, CEO of ADA-ES said, “We are very pleased to welcome this additional investment by Goldman Sachs. We believe that their continued financial interest in Clean Coal further validates the environmental and financial benefits of this proven emissions control technology.

“As we continue to assess ADA’s liabilities resulting from the arbitration panel’s recent interim award to Norit Americas, Inc. and related indemnity obligations, this cash infusion enhances our balance sheet and our ability to fulfill those obligations.”

ADA-ES is a leader in clean coal technology and the associated specialty chemicals, serving the coal-fueled power plant industry.

OXiGENE Inc. (OXGN) surges on new cancer treatment

Monday, June 6th, 2011

OXiGENE Inc. (Nasdaq: OXGN) shares rose 13.8% to $4.87, after the biotech company on Saturday reported encouraging data on a potential treatment for non-small cell lung cancer. Share volume for the stock tallied 2.3 million shares, already surpassing an all-day high of 1.7 million.

The San Francisco-based company announced Saturday that it presented updated safety and clinical activity data from the FALCON trial, a stratified randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine, or CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

An updated analysis conducted approximately 11 months after the enrollment of the last patient in June 2010 showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT Arm) was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. In addition, a pre-specified subgroup analysis showed meaningful improvements in median time to progression for patients with poor performance status.

Said Dr. Peter Langecker, CEO of OXiGENE, “With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of ZYBRESTAT.

“In addition,” Langecker continued, “this study provides data in non-small cell lung cancer (NSCLC) suggesting that ZYBRESTAT may benefit patients with more advanced stages of disease…. We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy and we look forward to discussing further development of ZYBRESTAT with potential pharmaceutical partners.”

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company’s major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.